Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately ...

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive.

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board ...

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE ... Meanwhile, Sage remains committed to its mission of making ZURZUVAE the standard treatment for women with postpartum depression as the Board evaluates ...

Sage’s shareholders do not need to take any action at this time. Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver ...